Recombinant vesicular stomatitis virus-Zaire Ebola virus will Drive the market till 2026 owing to increase in the prevalence of Ebola disease coupled with a rise in Ebola vaccination across the globe.

global Ebola Vaccine market

According to GMI Research, the growth opportunities in the Ebola Vaccine market look promising over the next couple of years. A global increase in the prevalence of Ebola disease coupled with a rise in Ebola vaccination across the globe are driving the market revenues towards USD XX million in 2026 from USD XX million in 2018. GMI Research expects the market to grow at a robust CAGR of XX% from 2019-2026.

In addition, increasing research and development around the world and expected launch of various Ebola vaccines in the upcoming few years are anticipated to driving market growth. Moreover, rising awareness, adequate funding, governments and non-governmental organizations initiative are factors creating growth opportunity for the Ebola vaccine market during the forecast period. However, outbreak of Ebola is unpredictable and may have an impact on the drug commercial market.

Recombinant vesicular stomatitis virus-Zaire Ebola virus segment type captured the largest market share in 2018 and will continue to dominate the market share through 2026 as more R&D activities are going on for the development of more vaccines. In addition, funding from the governments and  non-government agencies and preventative use across a broad population base will further drive the growth. The chimpanzee adenovirus type 3-Zaire Ebola virus segment accounts for the second-highest share in terms of revenue in 2018, however the market is expected to grow at the fastest rate through 2026.

 “Growing demand for novel diagnostic equipment and medicines among end-users, coupled with rising funding for R&D activities related to Ebola treatment are major factors driving the growth of the global Ebola vaccine market.”—-GMI Research Outlook

Based on geography, North America is the largest market in 2018 for the Ebola vaccine due to the presence of leading players and high vaccine development rates in the region. Asia-Pacific is expected to witness higher growth over the forecast period, primarily due to an increase in a government initiative to spread awareness about the Ebola vaccine in this region. However, the cost associated with the clinical phase is relatively lower in countries such as, India and China, and ease in the regulatory and filing process to overcome expenses significantly are the key bolstering factors which expected to drive the market growth.

Key takeaways/key essentials:

  • In 2016, GlaxoSmithKline plc has developed CAd3-ZEBOV vaccine. This vaccine is derived from chimpanzee adenovirus.

Global Ebola Vaccine market share is divided by some of the key players including, Various notable players operating in the market include Sarepta Therapeutics Inc., Mapp Biopharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Merck & Company, Inc., GlaxoSmithKline plc., Novavax Inc., GeoVax Labs Inc., Ltd among others among others.

The global Ebola Vaccine market has been segmented based on virus strain and key geographies. Based on the virus strain, global Ebola Vaccine market has been segmented into Chimpanzee Adeno virus type 3-Zaire Ebola virus, Recombinant vesicular stomatitis virus-Zaire Ebola virus and Adeno virus serotype 26- Zaire Ebola Virus.

The research report on Ebola Vaccine Market provides in-depth analysis of the global Ebola Vaccine market revenue based on virus strain and major geographies for the forecast period from 2019 to 2026. The report highlights the major market drivers propelling the growth as well as challenges faced by the market participants. The research report also provides market size and forecast for Ebola Vaccine market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For more details, browse the Table of Contents:
Early buyers will get customization upto 25% on report

Contact Sarah Nash
Tel: +353 1 536 3035
U.S Office +1 860 881 2270
Europe Office +353 1 442 8820
Email: [email protected]

error: Content is protected !!